The Association for Accessible Medicines has painted an encouraging picture of ongoing savings made by US patients through generic and biosimilar competition in its 2022 US Generic and Biosimilar Medicines Savings Report. However, consumers were seen to overpay for off-patent drugs even as savings increase.
“Today, as a result of pervasive profit-seeking by middlemen, such as pharmacy benefit managers, patients often pay more than they should for generics or are even prevented entirely from receiving lower-cost generics and biosimilars